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Acute lymphoblastic leukemia is the most common malignancy in children. Although it is
now curable in 80–90% of cases, patients withT-cell acute lymphoblastic leukemia (T-ALL)
experience a higher frequency of induction failure and early relapse. Despite aggressive
treatment approaches, including transplantation and new salvage regimens, most children
with relapsed T-ALL will not be cured. As such, we are in need of new targeted therapies
for the disease. Recent advances in the molecular characterization ofT-ALL have uncovered
a number of new therapeutic targets. This review will summarize recent advancements in
the study of inhibiting the NOTCH1, PI3K–AKT, and Cyclin D3:CDK4/6 pathways as thera-
peutic strategies for T-ALL. We will focus on pre-clinical studies supporting the testing of
small-molecule inhibitors targeting these proteins and the rationale of combination thera-
pies. Moreover, epigenetic approaches to modulate T-ALL are rapidly emerging. Here, we
will discuss the data supporting the role of bromodomain and extra-terminal bromodomain
inhibitors in human T-ALL.
Keywords:T-cell acute lymphoblastic leukemia, NOTCH1, cyclins, cyclin-dependent kinases, PI3K/AKT/mTOR, PI3K
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While cure rates for children with acute lymphoblastic leukemia
(ALL) have dramatically improved over the last several decades,
ALL still remains a leading cause of cancer-related death in chil-
dren. For adults with ALL, progress has been rather modest. One
high-risk ALL subtype, T-cell acute lymphoblastic leukemia (T-
ALL), accounts for 10–15% of pediatric and 25% of adult ALL
cases. Although treatment of T-ALL has improved, early relapse is
common and is almost invariably associated with poor prognosis.
Furthermore, a major challenge remains the lifelong morbidity
suffered by patients treated with current chemotherapy regimens.
We are in need of more effective and selective treatment strategies.
In this review, we will focus on emerging druggable opportuni-
ties in T-ALL: NOTCH1, BRD4/MYC, Cyclin D3:CDK4/6, and the
PI3K pathway.
NOTCH PATHWAY MUTATIONS
Notch signaling is a critical driver of T-cell differentiation (1),
specifically the commitment of lymphoid precursors to the T-cell
fate, as well as to subsequent thymocyte development (2–5). Thus,
it is not a surprise that aberrancies in Notch signaling are one
of the major oncogenic events in T-ALL. Gain-of-function muta-
tions in NOTCH1 are the most common genetic abnormalities
reported in T-ALL. Activating mutations of NOTCH1 are present
in 55–60% of T-ALL cases (6). Chromosomal rearrangements
involving NOTCH1 t (7;9)(q34;q34.3) have been characterized
in human T-ALL and lymphoma (7, 8), and NOTCH1 muta-
tions have also been reported in 5.3–20% of chronic lymphocytic
leukemia (CLL) (9, 10). Mutations that inactivate the Notch path-
way have been described in a number of human cancers, such as
chronic myelomonocytic leukemia (CMML) (11) and squamous
cell malignancies involving the skin, head, and neck (12, 13),
indicating that Notch signaling can be either oncogenic or tumor
suppressive depending on the cellular context. NOTCH1 encodes
for a transmembrane receptor activated through a series of prote-
olytic cleavage events. In normal mammalian signaling, canonical
NOTCH1 pathway activation relies on ligand-induced (Delta-like
1, 3, 4 or Jagged/Serrate 1 or 2) cleavage of the receptor that results
in release of the intracellular domain of Notch (ICN). This process
is mediated by γ-secretase, a multi-subunit protease complex that
cleaves single-pass type I integral membrane proteins at residues
within the transmembrane domain. ICN1 then translocates to the
nucleus, associates with other proteins as a member of a transcrip-
tion factor complex and initiates highly diverse transcriptional
programs that govern an array of cellular functions (1).
Notch receptors have a modular domain organization. The
ectodomains of Notch receptors consist of a series of N-terminal
epidermal growth factor (EGF)-like repeats, responsible for ligand
binding, followed by three LIN-12/Notch repeat (LNR) modules
that prevent receptor activation. Next, the heterodimerization
domain (HD) links the extracellular tail to ICN1, the domain
involved in transcriptional regulation. ICN1 consists of a RAM
domain, seven ankyrin (ANK) repeats flanked by two nuclear
localization signals (NLS), a transactivation domain (TAD), and a
PEST region that participates in protein degradation. The major-
ity of leukemogenic mutations are located in either the HD or
PEST domains (6). Notch activation through class I HD mutations
occurs by single amino acid substitutions or in-frame insertions
or deletions that reduce the stability of the LNR–HD complex and
generate a constitutively active, ligand-independent Notch protein
(6, 14). Class II HD mutations are longer insertions located at the
distal part of the HD domain that expose the proteolytic cleavage
site (S2) to the activity of the extracellular ADAM metalloprotease
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causing high levels of ligand-independent activation of NOTCH1
(6). A third class of mutation, juxtamembrane expansion mutants
(JME), are internal tandem duplications in the 3′ end of intron
27 and/or the proximal region of exon 28, which result in high
level of activation due to the increased separation of the HD–LNR
repeat complex from the membrane (15). In contrast, NOTCH1
PEST mutations delete the C-terminal part of the receptor impair-
ing the degradation of activated NOTCH1. Similarly, mutations in
FBXW7, a gene that encodes an ubiquitin ligase, mimic the effect
of NOTCH1 PEST deletions thus increasing the stability of ICN1.
Several studies strongly support the development of NOTCH1
inhibitors for targeted cancer therapy, particularly for T-ALL,
where recurrent NOTCH1 mutations are common and cancer
dependency has been well established (16–21). For example, sev-
eral reports have shown that transgenic expression of ICN1 leads to
the rapid development of aggressive T-cell leukemia/lymphomas
(7, 20). Furthermore, Demarest and colleagues demonstrated that
c-Myc expression cannot fully rescue a T-ALL tumor when Notch1
expression is extinguished in a transgenic mouse model indicat-
ing that tumor maintenance is dependent on oncogenic Notch
signaling (21).
Given NOTCH1’s important role in the pathogenesis of T-
ALL, and its activation through a series of proteolytic cleavage
events, it is a propitious target for drug development (Figure 1).
The first and most comprehensively studied approach to target-
ing NOTCH1 is the inhibition of the γ-secretase complex. γ-
Secretase inhibitors (GSIs) were originally identified in cell-based
drug screens for inhibitors of β amyloid production, considered
a causative event in the development of Alzheimer disease (AD).
Because the γ-secretase complex is a chemically tractable target,
several potent, orally available, brain penetrant small molecules
have been developed and tested in pre-clinical studies and in
humans with AD and cancer. Despite promising pre-clinical stud-
ies with the GSI MK-0752 in NOTCH1-mutated T-ALL cell lines
FIGURE 1 | Schematic representation of NOTCH1 signaling. The
Notch receptor is cleaved by furin (S1 cleavage) in the Golgi and then
matures to the cell membrane. In physiological conditions, the binding of
Delta or Jagged ligand to the Notch receptor initiates two consecutive
proteolytic cleavage events; the first is mediated by the ADAM protease
TACE and occurs on the extracellular side of Notch near the
transmembrane domain (S2). The second cleavage (S3) occurs within the
transmembrane domain and is mediated by the activity of γ-secretase, a
complex composed of four proteins: presenilin (PS1/2), nicastrin (NCT),
APH-1, and PEN-2. Intracellular NOTCH1 (ICN1) is released and
translocates to the nucleus. In the nucleus, ICN1 binds to the CSL
transcription factor, converting it from a transcriptional repressor into a
transcriptional activator while recruiting the coactivator MALM1. In red
are indicated approaches to inhibit Notch signaling.
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(16, 22), the first phase I clinical trial testing this molecule in
patients with T-ALL showed limited antitumor activity, and the
continuous dosing regimen was associated with severe gastro-
intestinal (GI) toxicity (23). Subsequently, it was demonstrated
that GSI inhibition leads to a decrement in normal NOTCH1 and
NOTCH2 signaling in the GI tract causing alteration of the prolif-
erative compartment and accumulation of mucus-secreting goblet
cells in the gut epithelium, thus explaining the severe diarrhea
in treated patients (24, 25). Although these side effects preclude
the continuous administration of single agent GSIs, they can
be attenuated with intermittent drug dosing. Alternatively, pre-
clinical studies demonstrated that the combination of a GSI and
dexamethasone dramatically attenuated GI toxicity and showed
enhanced anti-leukemia properties in T-ALL models (24, 26, 27).
An alternative approach to targeting Notch has focused on the
development of antibody-based therapy directed against specific
components of Notch receptors and their ligands. Because the
Notch-Delta-Like 4 (DLL4) axis lies downstream of initiating sig-
nals induced by vascular-endothelial growth factor (VEGF), its
inhibition has been regarded as a promising new targeted ther-
apy in tumor angiogenesis (28). To inhibit the NOTCH1–DLL4
receptor–ligand interaction different approaches have been used,
including the development of monoclonal antibodies (29), decoy
ligands (30), and decoy receptor molecules (31, 32). Preliminary
studies showed tumor regression using this approach (29, 33),
although prolonged treatment has been associated with the devel-
opment of vascular-endothelial cell-based tumors and liver toxic-
ity in mice, necessitating an intermittent dosing schedule (34–36).
More relevant for a T-ALL application is the development of anti-
bodies inhibiting Notch signaling independently from its interac-
tion with ligands. Inhibitory antibodies against the NOTCH1 (35,
37) and NOTCH2 (37) negative regulatory region (NRR) have
been reported. By targeting the NRR region, which spans from the
LNR to the HD domain, both groups identified a mechanism to
lock Notch signaling in the off state. Both demonstrated that anti-
NRR antibodies inhibit growth of NOTCH1-driven T-ALL cell
lines. Furthermore, Wu and colleagues demonstrated that anti-
NRR1 can dramatically decrease growth in pre-clinical xenograft
models (37). Interestingly targeting NRR1 or NRR2 had no effect
on weight in treated mice, a remarkable contrast with the nearly
20% weight loss caused by inhibiting both receptors simultane-
ously, a known undesired effect previously observed in animal
models and patients treated with GSIs (37). These first studies
on selective inhibition of NOTCH1 and NOTCH2 showed that
individual dosing with isoform-specific antibodies generated few
(NRR1) or no (NRR2) changes to intestinal morphology and
so suggest that selective inhibition of Notch receptors is feasi-
ble and effective in T-ALL models and leads to diminished gut
toxicity.
An additional example relies on the development of antibod-
ies raised against components of the γ-secretase complex, such as
nicastrin. A5226A, a monoclonal antibody against the extracellular
domain of nicastrin, inhibits the γ-secretase activity by competing
with the substrate binding in vitro. Only a moderate decrement
of ICN1 was observed upon A5226A treatment in DND41 cells
in vitro, but a significant reduction in tumor volume for DND41
xenotransplants was observed (38).
While pre-clinical studies strongly support the development of
new Notch inhibitors in human cancers, the discovery of alter-
native Notch pathway antagonists with a different mechanism
of action from GSIs or Notch-directed antibodies represents a
challenge. Historically, transcription factors have been considered
among the most chemically intractable of protein targets because
they mediate their action largely through protein–protein and
protein–DNA interactions rather than enzymatic activities and
because designing high-throughput screening assays to measure
these interactions is difficult. One potential approach to directly
target the Notch complex might use a stapled peptide technol-
ogy (39). A second is based on the premise that one can target a
transcription factor abnormality by identifying compounds that
successfully target its deranged transcriptional program (40).
Our laboratory applied Gene Expression-based High-
throughput Screening (GE-HTS) (41), a screening approach that
leverages the assessment of gene expression signatures as surro-
gates for different biological states. A 28 gene expression signa-
ture for the NOTCH1 activated state was defined and adapted
to the GE-HTS assay, which uses ligation-mediated amplification
(LMA) and a Luminex bead-based detection system. Three thou-
sand eight hundred one compounds were screened and results
of the chemical screen integrated with those of a complemen-
tary cDNA library screen for factors that enhance the signaling
activity of the NOTCH1 mutant L1601P∆P. The P-type ATPase
SERCAs emerged at the nexus of these two complementary screens
as a potential therapeutic target in NOTCH1-associated T-ALL.
Briefly, the SERCA inhibitor thapsigargin down-regulated the
expression of the NOTCH1 target genes, and similar to GSIs,
induced a G0/G1 arrest and a decrease in cell size. We demon-
strated that thapsigargin inhibits Notch signaling by altering its
normal maturation. Treatment with low nanomolar concentra-
tions of thapsigargin led to a marked decrement in transmembrane
and activated NOTCH1 while unprocessed, full-length NOTCH1
receptors accumulated in the endoplasmic reticulum (ER)/Golgi
compartment. This result was supported by the prior observa-
tion that Ca-P60A (SERCA homolog) deficiency leads to a Notch
maturation defect in Drosophila (42). We also confirmed that
SERCA inhibition induces on target anti T-ALL activity in vitro
and in T-ALL xenograft models in vivo. Moreover, T-ALL cell lines
expressing leukemogenic NOTCH1 HD domain mutations were
more sensitive to the SERCA inhibitor thapsigargin than normal
receptors, supporting the possibility of a therapeutic window for
compounds of this class (40).
Subsequent studies confirmed that targeting the Notch secre-
tory pathway may represent an alternative mechanism to inhibit
Notch signaling. Kramer and colleagues (43) developed a high-
content screening assay to identify new regulatory proteins
involved in Notch trafficking and processing in human cells. This
assay relied on the generation of constitutively active, ligand-
independent, Notch∆E-eGF stable cell lines in which nuclear
eGFP staining was the surrogate measure of Notch activation. The
authors identified four γ-secretase modulators and the dihydropy-
ridine FLI-06. They demonstrated that FLI-06 inhibits Notch traf-
ficking early in the protein secretary pathway (43). Although the
precise protein target of FLI-06 is yet to be determined, this finding
is particularly important because new candidate targets/molecules

























































Roti and Stegmaier New approaches to target T-ALL
regulating Notch trafficking are rapidly emerging in studies of
Notch in other model organisms (44).
BRD4/MYC
The bromodomain (BRD) is a conserved protein motif of ~110
amino acids that recognizes and binds ε-N -acetylated lysine
residues in histone and non-histone proteins. Through this inter-
action, bromodomain-containing proteins facilitate the anchoring
of nuclear macromolecular complexes to specific acetylated nucle-
osome sites on chromatin and control several biological processes
including DNA replication, DNA damage repair, chromatin
remodeling, and transcription regulation (45). The bromodomain
and extra-terminal (BET) family of proteins, defined by tan-
dem BET domain, include BRD2, BRD3, BRD4, and BRDT. BET
proteins play a key role in many cellular processes, including
gene expression, mitosis control, and viral–host interaction and
more recently have emerged as potential therapeutic targets in
cancer (46).
The last year has seen the rapid development of multiple small-
molecule inhibitors of BET bromodomains by both academic
groups and pharmaceutical companies, with JQ1 among the first
in class. JQ1 is a novel thieno-triazolo-1,4-diazepine that binds
selectively and with high affinity to the acetyl lysine pocket of the
conserved BET domains of the BRD protein family (Figure 2A).
FIGURE 2 | Potential targets inT-ALL: PI3K/AKT/mTOR, cyclin
D3:CDK4/6, BRD4/MYC. (A) BET bromodomain inhibitors displace BET
bromodomain, such as BRD4, from chromatin by competitively binding to
the acetyl lysine recognition pocket and lead to the repression of BRD4
transcriptional targets. (B) CDK4/6 inhibitors specifically inhibit CDK4 and
6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early
G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S-phase
transition, thereby arresting the cell cycle in the G1 phase, suppressing
DNA synthesis, and inhibiting cancer cell growth. (C) PI3K catalyzes
phosphorylation of the D3 position on phosphoinositide to generate the
second messenger phosphatidylinositol-3,4-5 trisphosphate (PIP3) from
phosphatidylinositol-3,4 bisphosphate (PIP2). PIP3 binds to the pleckstrin
homology (PH) domains of the 3′ phosphoinositide-dependant kinase
(PDK-1) and AKT causing both proteins to translocate to the cell
membrane where they are subsequently activated. AKT activation
stimulates metabolism, cell-cycle progression, survival and migration
through phosphorylation of many physiological substrates, including
mTOR. The tumor suppressor PTEN inhibits PI3K signaling by the
dephosphorylation of PIP3. AKT can activate mTOR directly by
phosphorylation at S2448 or indirectly by inhibition of the tuberous
sclerosis complex TSC2. Potential inhibitors of the above described
pathway are indicated in red.

























































Roti and Stegmaier New approaches to target T-ALL
Its activity was first described in NUT midline carcinoma, a rare,
aggressive epithelial cancer genetically defined by a chromosomal
translocation of BRD4 with NUT (47), where JQ1 inhibition of
BRD4 induced squamous cell differentiation and tumor regression
in a tumor primagraft model (48). Evidence of BRD4 depen-
dency in human malignancies was later extended to acute myeloid
leukemia (AML). In screening a short hairpin RNA (shRNA)
library targeting chromatin regulators in an MLL-AF9 model of
AML, BRD4 was found to be critical for disease maintenance, and
inhibition with JQ1 ablated the expression and function of MYC
itself (49). This compound class has been reported to be active
in a number of diseases dependent on either MYC or MYCN,
including neuroblastoma, medulloblastoma, multiple myeloma,
and non-Hodgkin Lymphoma (NHL), to name a few (50–54).
In T-ALL, multiple lines of evidence now suggest a role for tar-
geting MYC with BET bromodomain inhibitors. First, NOTCH1-
mediated activation of MYC is important to the maintenance
of leukemic growth (55). Second, two recent studies support
the role for MYC in T-ALL leukemia initiation and demonstrate
anti-leukemic activity with BET bromodomain inhibitors, includ-
ing JQ1. In a study by King et al., dependence on MYC for
leukemia-initiating cell (LIC) activity was demonstrated using a
mouse model of the Fbxw7R468C substitution, an event commonly
observed in human T-ALL leading to the stabilization of NOTCH
and MYC proteins (56). These investigators next explored the inhi-
bition of BRD4 as a therapeutic strategy for downregulating MYC
in T-ALL. They demonstrated that knockdown of Brd4 and Myc
inhibited growth in Notch1-positive mouse T-ALL cell lines, and
JQ1 treatment showed a significant dose-dependent decrease in
cellular growth along with reduction in MYC protein expression
in a panel of T-ALL cell lines and in primary human T-ALL samples
tested in vitro. This decrease in cellular growth could be partially
rescued with overexpression of a MYC transgene. Human FBXW7
mutant T-ALL cell lines, that are typically GSI resistant, were also
sensitive to treatment with JQ1. Furthermore, a BET bromod-
omain inhibitor was demonstrated to have efficacy in vivo in both
Fbxw7+/+ and Fbxw7R468C/+ mouse models of T-ALL (56).
An independent study by Roderick et al. also demonstrated the
importance of MYC in the LIC in T-ALL. In this study, c-Myc
abrogation depleted leukemia LICs and prolonged survival in a
Notch1 mutant Tal1/Lmo2 T-ALL mouse model (57). Pharmaco-
logical inhibition with JQ1 of Tal1/Lmo2 T-ALL murine cell lines
demonstrated that Brd4 inhibition induced an initial cell-cycle
arrest followed by apoptosis, in contrast to GSI, which predom-
inantly induced cell-cycle arrest with minimal apoptosis. These
effects were partially rescued by the overexpression of an exoge-
nous murine c-Myc construct supporting that c-Myc is a relevant
target of Brd4 in mouse T-ALL. In order to test whether JQ1 inter-
feres with leukemia initiation and reduces LICs, Tal1/Lmo2 mouse
T-ALLs were transplanted into syngeneic recipients and vehicle or
JQ1 administered for 3 weeks. JQ1 significantly increased overall
survival and depleted LICs, further supporting the critical role of
c-Myc in mouse LIC maintenance. Further testing of JQ1 con-
firmed that BRD4 inhibition impaired the growth and induced
apoptosis in human T-ALL cell lines. In 8 out of 10 primary T-
ALL pediatric samples JQ1 inhibited cell growth and reduced MYC
levels. JQ1 was active even in cases of refractory or relapsed T-ALL.
Additional data generated in high-risk primary T-ALL short-term
culture assays demonstrated that JQ1 induced apoptosis and the
expression of the pro-apoptotic factor BIM, indicating that BIM
may be repressed downstream of MYC (58).
As discussed above, the translation of GSIs into the clinic has
been tempered by a lack of cytotoxic antitumor responses and by
severe GI toxicity associated with inhibition of Notch signaling
in the intestinal epithelium (24, 25). A recent study sheds light
on one potential mechanism of resistance to GSI in T-ALL that
might be targeted with BET bromodomain inhibitors. The authors
identified a subpopulation of drug-tolerant T-ALL cells called
“persisters” that developed with long-term in vitro GSI treatment.
Because the “persister” phenotype was reversible after γ-secretase
withdrawal the authors hypothesized an epigenetic mechanism of
drug resistance. To test this hypothesis they performed a shRNA
screen targeting nearly 350 chromatin regulator genes. Among top
hits, which preferentially impaired the viability of “persister” cells
while sparing the naïve population, they identified BRD4. Consis-
tent with this model, “persister” cells were more sensitive to BRD4
inhibition in vitro, and combination therapy with GSI and JQ1
in a GSI “naïve” T-ALL xenotransplant model was more effective
than either drug alone (59).
The effects of BRD inhibition are not limited to MYC transcrip-
tion. For example, genome-wide expression profiling following
JQ1 treatment identified IL7R, along with MYC, to be among the
most down-regulated genes, and early studies correlated BRD4
inhibition with decreased IL7R expression and loss of BRD4 load-
ing at the IL7R promoter across different cancer subtypes (60).
Activating mutations in IL7R were recently identified in at least 9%
of pediatric T-ALL, and constitutive activation of IL7R signaling
in CD4−/CD8− mice thymocytes induced early T-cell precursor
ALL (ETP-ALL) (61).
Finally, BRD-targeted pharmacological inhibition in T-ALL
is being tested in the clinic. Currently, OTX015, a synthetic
small molecule against BRD2, 3, and 4 is under evaluation in a
phase 1b dose-escalation trial in relapsed or refractory AML/ALL
(NCT01713582) following promising in vivo data showing cell-
cycle arrest and apoptosis at submicromolar doses in a panel of
leukemia cells (62).
Taken together, these data provide multiple lines of evidence
to support testing BET bromodomain inhibitors in patients with
T-ALL. Multiple BET bromodomain inhibitors have entered the
clinic and are currently in testing in phase I clinical trials, including
trials testing this compound class in patients with leukemia.
D-TYPE CYCLINS
D-type cyclins, together with cyclin-dependent kinases (CDKs),
control G1 to S-phase progression and initiate DNA replication
in response to mitogenic signals in many different cell types.
The binding of D-type cyclins (D1, D2, and D3) to CDK4 or
CDK6 leads to phosphorylation of the retinoblastoma protein
(Rb). Phosphorylated Rb is inactive and unable to bind the tran-
scription factor E2F1, leading to transactivation of E2F-dependent
genes and progression to S phase. Because these proteins are widely
expressed in many tissues, there was initial concern about the
therapeutic window of CDK inhibitors. However, several studies
have demonstrated that the absence of individual D-type cyclins
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is dispensable for proliferation and for the development of the
majority of organs, suggesting a redundant function of these
proteins in many circumstances (63–65).
Altered expression of cyclin-D genes (CCND) has been
implicated in the pathogenesis of numerous cancers, including
hematopoietic malignancies. The t (11;14)(q13;q32) translocation
at the CCND1 locus is a hallmark of mantle cell lymphoma (66),
and molecular studies revealed activating mutations in the phos-
phorylation site of cyclin-D genes in DLBCL, CLL, and Burkitt
lymphoma (10, 67, 68). Moreover, D-type cyclins were shown to
be essential for tumor initiation in vivo. Mice lacking cyclin-D1
are resistant to ErbB2-driven carcinoma (69–72), while cyclin-
D3-null animals are refractory to NOTCH1-induced T-ALL (73).
Thus, modulation of cyclin-D CDK complexes appears a potential
therapeutic strategy in several human malignancies.
Multiple groups have reported inhibition of D-type cyclins–
CDK complexes as a potential therapeutic strategy for patients
with T-ALL (Figure 2B). Sicinska et al. first demonstrated that
cyclin-D3−/− animals are refractory to Notch1-driven T-ALL
development, and knockdown of cyclin-D3 significantly inhibits
proliferation in T-ALL cell lines corresponding to immature thy-
mocytes with rearranged TCRB chains (73). Choi et al. substan-
tiated the role of cyclin-D3 in Notch1-driven leukemia estab-
lishment in vivo; acute ablation of cyclin-D3 in mice trans-
duced with activated Notch-ICD reduced the number of leukemic
clones and significantly extended survival. In vivo pharmacological
inhibition of the cyclin-D3-associated kinases CDK4/6 by PD-
0332991 resulted in reduction of tumor burden and improved
survival in mice transduced with activated Notch-ICD. In this
model, treatment with PD-0332991 inhibited cell-cycle progres-
sion and induced apoptosis, phenocopying the effects of acute
genetic loss of cyclin-D3. Reduced leukemic burden and pro-
longed survival was also seen following PD00332991 treatment
in two human T-ALL cell lines xenograft models, further suggest-
ing CDK4/6 modulation as a potential strategy for Notch-driven
T-ALL malignancies (74).
A second group simultaneously reported the requirement for
Cyclin-D-kinase activity in T-ALL leukemia maintenance. Sawai
and colleagues reported that PD-0332991 inhibition of CDK4/6
efficiently inhibited S-phase entry in a panel of human NOTCH1-
mutated T-ALL cell lines and in two primary T-ALL patient sam-
ples tested in vitro. They showed that G0/G1 arrest was associated
with a decrement of pRb (S807/811), an increase in p27Kip1 and
repression of mitosis regulator genes, such as E2F2,CCNA2, SKP2,
CDC25a,CCNE2, andCDT1. Furthermore, prolonged exposure to
PD-0332991 led to apoptosis as observed by a significant increase
in Annexin V. Pre-clinical studies were conducted in two different
in vivo models: an ICN1-EGFP-transduced bone marrow trans-
plantation model in B6SJL mice and a CEM human T-ALL cell
line xenograft model. PD-0332991 treatment significantly pro-
longed survival and dramatically decreased leukemic burden in
both models. Induction of apoptosis in the ICN1-EGFP+ cells was
observed in the syngeneic model. This work also demonstrated
that cyclin-D3 has a unique role in the expansion of normally
developing T-cell progenitors and in the induction of T-ALL.
Forced in vivo expression of cyclin-D2 did not compensate for the
lack of cyclin-D3, suggesting intrinsic differences in the function
of these two proteins in T-cell development (75). Collectively, these
studies demonstrate a new avenue for targeted therapies directed
against cell-cycle regulators in T-ALL. With CDK4/6 inhibitors
already being tested in the clinic for other diseases these findings
are readily translatable.
PI3K/PTEN/AKT/mTOR
PI3K/PTEN/AKT/mTOR is a critical pathway that elaborates both
intracellular and extracellular signals to control cell metabolism,
proliferation,and survival. Because several mechanisms can lead to
PI3K/PTEN/AKT/mTOR activation, aberrancies of this pathway
are frequently observed in human malignancies (76–79). Targeted
inhibition of individual nodes in the pathway is under investi-
gation as a cancer therapy strategy (Figure 2C). PI3K catalyzes
the phosphorylation of phosphoinositide to generate the second
messenger phosphatidylinositol-3,4,5 trisphosphate (PIP3) from
phosphatidylinositol-3,4 bisphosphate (PIP2). PIP3 binds to the
pleckstrin homology (PH) of the phosphoinositide-dependent
kinase-1 (PDK-1) and the serine/threonine kinase AKT, causing
both proteins to translocate to the cell membrane where they
are subsequently activated. The tumor suppressor PTEN (phos-
phatase and tensin deleted on chromosome 10) antagonizes PI3K
signaling by the dephosphorylation of PIP3. AKT can activate
mTOR at least through two distinct mechanisms: directly by phos-
phorylation at the S2448 site or indirectly by inhibition of the
tuberous sclerosis complex 2 (TSC2).
Cross talk between Notch signaling and the PI3K/PTEN/AKT
pathway is under active investigation. Compelling evidence that
Notch activates AKT was supported by work of Palomero and col-
leagues (78, 80). The authors demonstrated that HES1 (hairy and
enhancer of split 1), a direct target of NOTCH1, binds to the PTEN
promoter and represses its activity resulting in decreased PTEN
expression and an increase in phosphorylation of AKT-Ser473.
Thus, activated NOTCH1 signaling promotes activation of PI3K–
AKT due to the transcriptional repression of PTEN. Treatment
with the NOTCH1 inhibitor Compound E diminished HES1 and,
as expected by the described model, restored PTEN activity. In
turn, PI3K–AKT was inhibited causing impaired cellular viabil-
ity. In summary, in a T-ALL background with an intact PTEN
axis, GSI treatment causes a dual inhibition of Notch and PI3K–
AKT signaling. Although this scenario is expected in two-thirds
of T-ALL cases, deletion and/or inactivating mutations of PTEN
have been described in 36% of primary T-ALL cases. Moreover, all
told, mutations of individual components of the PI3K/AKT axis,
including PTEN, are observed in 47% of pediatric T-ALL cases
(79). In the T-ALL cases of PTEN deletion, despite NOTCH1–
HES1 inhibition, the PI3K–AKT signaling will be maintained in
an active tone, impairing full response to NOTCH1 inhibition,
thus accounting for one potential intrinsic resistance mechanism
to GSI treatment (80).
Inhibition of the isoforms PI3K-γ and PI3K-δ is one candidate
strategy to target PTEN null T-ALL. Recent studies demonstrated
that PI3K-γ and PI3K-δ are required for the establishment of a
PTEN deficient leukemia in vivo (81). To test whether PI3K-γ and
PI3K-δ are required for tumor maintenance, the authors devel-
oped CAL-130, a small molecule that inhibits both the catalytic
domains of p110γ and p110δ. In Pten null mice with established
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T-ALL leukemia CAL-130 increased survival and reduced tumor
burden in the cohort of treated animals. Furthermore, testing in
T-ALL cell lines demonstrated the ability of CAL-130 to inhibit
cellular growth while inducing apoptosis. Finally, cell lethality was
further demonstrated in a panel of primary T-ALL samples lacking
PTEN expression (81).
Because constitutive activation of PI3K signaling is common in
T-ALL, PI3K inhibitors are being studied as a treatment strategy
for this disease. For example, the novel dual PI3K/mTOR inhibitor
NVP-BEZ235, an orally bioavailable imidazoquinoline derivative,
proved to have anti-proliferative effects in several T-ALL cell lines
where pro-apoptotic effects were demonstrated (82). An ongo-
ing trial is currently testing this molecule in AML, ALL, and
CML. A second example evaluated the activity of NVP-BKM120,
a potent, orally available, pan-PI3K inhibitor. In human T-ALL
cell lines, NVP-BKM120 induced apoptosis and cell-cycle arrest
(G2/M transition). Additionally, cell lethality was confirmed in
primary T-ALL lymphoblasts. As expected, NVP-BKM120 inhib-
ited AKT as shown by a dose-dependent reduction of phosphory-
lation at Ser473 and at Ser235/236 and the downstream target
RPS6. Finally, pre-clinical studies in a T-ALL cell line-derived
xenotransplant model demonstrated that NVP-BKM120 signifi-
cantly delayed tumor growth and prolonged survival (83). To date,
NVP-BKM120 has been tested in a dose-escalation trial in patients
with advanced solid tumors. It was safe and well tolerated and
was demonstrated to inhibit the target (84). An ongoing phase I
study (NCT01396499) is testing NVP-BKM120 in patients with
advanced leukemia. Additionally, other studies have supported
the inhibition of PI3K/AKT signaling as a treatment strategy,
including through the activation of PP2A (85).
Another approach to target the PI3K pathway would be to
target mTOR, the catalytic subunit of two distinct complexes
mTORC1 and mTORC2. mTORC1 controls the translational reg-
ulators S6K1 and 4E-BP1, whereas mTORC2 phosphorylates AKT
at Ser473 (86–88). The combined inhibition of mTOR and Notch
was shown to suppress T-ALL growth (89), and several pre-clinical
studies suggested that mTOR modulation can effectively reverse
glucocorticoid resistance in T-ALL (90–93). Single agent mTORC1
inhibitors are not likely to be an effective therapeutic therapy as
they provoke a cytostatic response and activate feedback loops
to enhance cell survival (94–97). The studies described above,
however, do support the testing of mTORC1 inhibitors in combi-
nations with other drugs, and these clinical trials are now ongoing
at several centers. Taken together, these studies support the con-
tinued testing of PI3K pathway inhibition as a therapeutic strategy
for T-ALL.
CONCLUSION
Despite unprecedented efforts to uncover the molecular com-
plexity of T-ALL, upfront treatment is still based on cytotoxic
chemotherapeutic regimens, and prognosis for this disease gen-
erally remains poor in adults and in both children and adults
with relapsed disease. The paucity of effective treatment options
available for patients of these unfavorable subgroups highlights
the importance of improving current therapies with molecu-
larly informed approaches. Targeting Notch, MYC/BRD4, Cyclin
D3:CDK4/6, and the PI3K pathway are promising therapeutic
targets in T-ALL, and the strong pre-clinical studies discussed
above support further investigation of these drugs in clinical trials
in patients with T-ALL.
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